Fruquintinib Capsules 1?mg ×?21 -Elunate
$1.00
Fruquintinib Capsules (brand: Elunate®) are potent, highly selective small-molecule inhibitors targeting VEGFR?1, VEGFR?2, and VEGFR?3. These capsules are used in preclinical oncology research—especially in studies of angiogenesis and colorectal cancer models. Each box contains 21 capsules of 1?mg each. Manufactured by Hutchison MediPharma (QC sub-licensee: Hutchison Pa—Indicated by code), produced by Hutchison-Med, and approved by China NMPA in 2018 under H20180015, product code 86910171000016
?? For laboratory research use only.?Please consult the staff for other purposes?
描述
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Fruquintinib Capsules (Elunate®) |
| Generic Name | Fruquintinib (HMPL?013) |
| Dosage Form | Oral capsule |
| Strength | 1?mg per capsule |
| Pack Size | 21 capsules per box |
| Approval Number | H20180015 (China NMPA) |
| Product Code | 86910171000016 |
| Manufacturer | Hutchison-owned Qilu (Suzhou) |
| Barcode | N/A |
| CAS Number | 1194506?26?7 :contentReference[oaicite:5]{index=5} |
| Molecular Formula | C??H??N?O? :contentReference[oaicite:6]{index=6} |
| Molecular Weight | ~393.4?g/mol :contentReference[oaicite:7]{index=7} |
| Storage | Store at room temperature, protect from moisture |
| Intended Use | Laboratory research only |
Mechanism of Action
Fruquintinib is a highly selective inhibitor of VEGF receptors 1, 2, and 3, blocking angiogenesis and tumor vascularization pathways in preclinical models of colorectal and other solid tumors hemonc.org+12pmc.ncbi.nlm.nih.gov+12en.wikipedia.org+12.
Research Applications & Pharmacology
-
Angiogenesis studies: Matrigel plug and tumor xenograft inhibition
-
Colorectal cancer research: Validated through Phase III FRESCO trial for mCRC adisinsight.springer.com+15pmc.ncbi.nlm.nih.gov+15en.wikipedia.org+15
-
Combination therapy: Often evaluated with chemotherapy agents in preclinical settings
-
Pharmacokinetics: Molecular weight ~393?g/mol; low aqueous solubility at pH 6.8, increases under acidic conditions
Safety Profile & Side Effects
Clinical data report common adverse effects including hypertension, hand–foot syndrome, proteinuria, and hepatotoxicity. Preclinical observations often mirror these findings. In lab environments, use PPE and monitor blood pressure and liver enzymes during animal studies .
?? Research?Use Disclaimer
This product is intended exclusively for laboratory research use. It is not approved for therapeutic, diagnostic, clinical, or veterinary applications. Misuse may pose safety risks or compromise data validity.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Fulvestrant?Faslodex? 0.25?g | EVER Pharma (Germany) | Price comparison
Fluvestrant (250?mg/5?ml) injectable solution, 2-vial set by EVER?Pharma Jena GmbH, Germany. A potent selective estrogen receptor degrader (SERD) used in advanced breast cancer research.
?? For laboratory research only – Not for human consumption or therapeutic use. $2.00 -
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00 -
Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison
Cetuximab NO1 Injection, 100?mg in 50?mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology.
?? For laboratory research use only – Not for human consumption or therapeutic use. $1.00 -
Granisetron Hydrochloride Dispersible Tablets Price comparison
A 5-HT? receptor antagonist—Granisetron Hydrochloride Dispersible Tablets by Guangxi Mingjian Pharmaceutical Co., Ltd. (Guimingjian). Packaged as 1?mg tablets, 4 tablets per blister × 2 blisters per box. Approved in China (NMPA No. H20020303; product code 86905130000183). Primarily intended for clinical prevention and treatment of nausea/vomiting induced by chemotherapy, radiation, or surgery. For research use only $1.00
评价
目前还没有评价